Related Experiment Video
Updated: Aug 17, 2026
Instrumentation of Near-term Fetal Sheep for Multivariate Chronic Non-anesthetized Recordings
Published on: October 25, 2015
Cost-effectiveness analysis of the use of digoxin immune Fab (ovine) for treatment of digoxin toxicity
1Center for Economics Research, Research Triangle Institute, Research Triangle Park, North Carolina 27709.
Insights
Digoxin immune Fab fragments (Digibind) effectively reverse digitalis toxicity, reducing mortality. While increasing costs for severely ill patients, they decrease expenses for less severe cases by reducing intensive care and interventions.
Area of Science:
- Pharmacology
- Toxicology
- Health Economics
Background:
- Digitalis toxicity is a significant cause of hospitalization and mortality annually.
- Digoxin immune Fab fragments (Digibind) offer a potential antidote for digitalis toxicity.
- Existing data on Digibind's clinical and economic impact require further analysis.
Purpose of the Study:
- To evaluate the clinical outcomes and medical care costs associated with Digibind treatment for digitalis toxicity.
- To differentiate the impact of Digibind based on the severity of digitalis toxicity (immediately life-threatening vs. not).
Main Methods:
- Analysis of uncontrolled studies and clinical data from patients treated with Digibind.
- Inclusion of pharmacokinetic and medical care data for symptomatically treated patients.
- Estimation of differences in clinical outcomes and costs for various patient subgroups.
Main Results:
- Digibind treatment significantly reduces mortality risk, particularly in severely toxic patients.
- For life-threatening toxicity, Digibind increases total medical costs due to increased survival and subsequent care ($1,900–$5,400 per life-year saved).
- For less severe toxicity, Digibind decreases total medical costs through reduced coronary care unit stays and fewer aggressive treatments.
Conclusions:
- Digoxin immune Fab fragments are effective in reversing digitalis toxicity and reducing mortality.
- The economic impact of Digibind varies by toxicity severity, offering cost savings in less severe cases.
- Digibind represents a valuable therapeutic option with a favorable cost-effectiveness profile, especially in life-threatening digitalis toxicity.
Abstract:
Each year many people have digitalis toxicity severe enough to require extensive hospital treatment. Digoxin immune Fab[ovine]-Fab fragments (Digibind) have been shown to reverse digitalis toxicity and substantially reduce the risk of death. Data were used from uncontrolled studies of patients treated with Fab fragments as well as clinical, medical care and pharmacokinetic data from symptomatically treated patients to derive estimates of the difference in clinical outcomes and medical care costs when treating with this new drug. Estimates are derived separately for treatment of patients with toxicity that is immediately life-threatening and patients whose manifestations are not immediately life-threatening. Treatment with Fab fragments reduces the probability of dying more for the seriously toxic than for the less seriously toxic patient. Such treatment is generally associated with an increase in total medical care costs for the seriously toxic patients because more of them survive the toxic episode and require additional medical care before discharge from the hospital. For these patients, the estimated cost per life-year saved is between $1,900 and $5,400. When Fab fragments are used to treat less seriously toxic patients, total medical care costs decrease because of an estimated decreased number of days in the coronary care unit and decreased use of pacemakers and other aggressive treatments.
